After last year's somewhat lacklustre M&A scene, 2010 started with the proverbial bang when the pharma industry's No 4, Novartis, yesterday announced it was forking out $28.1bn to buy the rest of Nestlé's share in the global specialised eye care leader Alcon ( www.clinica.co.uk, January 4 ...
Please Login to read the full article.
